Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD
Phase 2 head-to-head portion of the study to commence enrollment immediately
Read more at newswire.caProvided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.